Company’s 36-month beta value is 0.98.Analysts have differing opinions on the stock, with 18 analysts rating it as a “buy,” 5 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for EXAS is 185.85M, and currently, short sellers hold a 5.99% ratio of that floaft. The average trading volume of EXAS on June 10, 2025 was 2.79M shares.
EXAS) stock’s latest price update
Exact Sciences Corp (NASDAQ: EXAS) has seen a rise in its stock price by 3.32 in relation to its previous close of 54.63. However, the company has experienced a 2.92% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-05 that EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
EXAS’s Market Performance
EXAS’s stock has risen by 2.92% in the past week, with a monthly rise of 9.32% and a quarterly rise of 23.00%. The volatility ratio for the week is 1.06% while the volatility levels for the last 30 days are 1.62% for Exact Sciences Corp The simple moving average for the last 20 days is 0.68% for EXAS stock, with a simple moving average of 0.67% for the last 200 days.
Analysts’ Opinion of EXAS
Many brokerage firms have already submitted their reports for EXAS stocks, with Mizuho repeating the rating for EXAS by listing it as a “Outperform.” The predicted price for EXAS in the upcoming period, according to Mizuho is $60 based on the research report published on April 10, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see EXAS reach a price target of $52. The rating they have provided for EXAS stocks is “Sector Perform” according to the report published on March 13th, 2025.
Barclays gave a rating of “Overweight” to EXAS, setting the target price at $70 in the report published on January 23rd of the current year.
EXAS Trading at 12.67% from the 50-Day Moving Average
After a stumble in the market that brought EXAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.50% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXAS starting from Conroy Kevin T, who purchase 19,500 shares at the price of $51.35 back on Nov 13 ’24. After this action, Conroy Kevin T now owns 1,074,191 shares of Exact Sciences Corp, valued at $1,001,325 using the latest closing price.
Baranick Brian, the EVP, GM, Precision Oncology of Exact Sciences Corp, sale 929 shares at $70.00 during a trade that took place back on Oct 08 ’24, which means that Baranick Brian is holding 12,758 shares at $65,030 based on the most recent closing price.
Stock Fundamentals for EXAS
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.68 for the gross margin
The net margin for Exact Sciences Corp stands at -0.36. The total capital return value is set at -0.2. Equity return is now at value -36.89, with -16.87 for asset returns.
Based on Exact Sciences Corp (EXAS), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at 0.13. The debt to equity ratio resting at 1.05. The interest coverage ratio of the stock is -57.46.
Currently, EBITDA for the company is -788.73 million with net debt to EBITDA at -2.56. When we switch over and look at the enterprise to sales, we see a ratio of 4.53. The receivables turnover for the company is 10.11for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.73.
Conclusion
In a nutshell, Exact Sciences Corp (EXAS) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
